Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.
Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Although docetaxel has recently been shown to extend the survival of patients with CRPC in two large randomised phase III studies, subsequent treatment options remain limited for these patients. A greater understanding of the molecular causes of castration resistance is allowing a more rational approach to the development of new drugs and many new agents are now in clinical development. Therapeutic targets include the adrenal steroid synthesis pathway, androgen receptor signalling, the epidermal growth factor receptor family, insulin growth factor-1 receptor, histone deacetylase, heat shock protein 90 and the tumour vasculature. Drugs against these targets are giving an insight into the molecular pathogenesis of this disease and promise to improve patient quality of life and survival. Finally, the recent discovery of chromosomal translocations resulting in the upregulation of one of at least 3 ETS genes (ERG, ETV1, ETV4) may lead to novel agents for the treatment of this disease.
Attard
G
G
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK.
Sarker
D
D
Reid
A
A
Molife
R
R
Parker
C
C
de Bono
J S
JS
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002369:Castration; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011944:Receptors, Androgen / Q000187:drug effects
D000970:Antineoplastic Agents; D011944:Receptors, Androgen